
Evrydiki Kravvariti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9254826/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3 year prospective study. Rheumatology, 2022, 61, 3408-3413.	0.9	12
2	Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1013-1016.	0.5	43
3	Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. RMD Open, 2022, 8, e002279.	1.8	18
4	Oxidative stress and endogenous DNA damage in blood mononuclear cells may predict anti-SARS-CoV-2 antibody titers after vaccination in older adults. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166393.	1.8	4
5	Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic. Annals of the Rheumatic Diseases, 2021, 80, e60-e60.	0.5	41
6	Clinical value of amyloid-beta1-40 as a marker of thrombo-inflammation in antiphospholipid syndrome. Rheumatology, 2021, 60, 1669-1675.	0.9	5
7	Increased influenza vaccination rates in patients with autoimmune rheumatic diseases during the Covid-19 pandemic: a cross-sectional study. Rheumatology International, 2021, 41, 895-902.	1.5	15
8	The Relevance and Added Value of Geriatric Medicine (GM): Introducing GM to Non-Geriatricians. Journal of Clinical Medicine, 2021, 10, 3018.	1.0	12
9	Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. Vaccines, 2021, 9, 1179.	2.1	7
10	Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib. European Respiratory Journal, 2021, 57, 2003021.	3.1	3
11	The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmunity Reviews, 2020, 19, 102491.	2.5	75
12	Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic. Mediterranean Journal of Rheumatology, 2020, 31, 288.	0.3	9
13	Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. Frontiers in Immunology, 2019, 10, 487.	2.2	43
14	The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice. Mediterranean Journal of Rheumatology, 2019, 30, 63.	0.3	9
15	Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case–control study. Seminars in Arthritis and Rheumatism, 2018, 47, 883-889.	1.6	30
16	Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nature Reviews Rheumatology, 2018, 14, 727-740.	3.5	67
17	Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity. Rheumatology, 2018, 57, 2158-2166.	0.9	23
18	Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis. Autoimmunity Reviews, 2017, 16, 308-312.	2.5	83